

ATTACHMENT #9: Contract-Supported Publications of Cancer Research

LUNG CANCER

(Case-Control)

- 1. Childhood exposure to secondhand smoke and functional mannose binding lectin polymorphisms are associated with increased lung cancer risk.** [Olivo-Marston SE](#), [Yang P](#), [Mechanic LE](#), [Bowman ED](#), [Pine SR](#), [Loffredo CA](#), [Alberg AJ](#), [Caporaso N](#), [Shields PG](#), [Chanock S](#), [Wu Y](#), [Jiang R](#), [Cunningham J](#), [Jen J](#), [Harris CC](#). **Cancer Epidemiol Biomarkers Prev.** 2009 Dec; 18 (12):3375-83.
- 2. p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence.** [Fujita K](#), [Mondal AM](#), [Horikawa I](#), [Nguyen GH](#), [Kumamoto K](#), [Sohn JJ](#), [Bowman ED](#), [Mathe EA](#), [Schetter AJ](#), [Pine SR](#), [Ji H](#), [Vojtesek B](#), [Bourdon JC](#), [Lane DP](#), [Harris CC](#). **Nat Cell Biol.** 2009 Sep;11(9):1135-42.
- 3. Elevated lung cancer risk is associated with deficiencies in cell cycle checkpoints: Genotype and phenotype analyses from a case-control study.** [Zheng YL](#), [Kosti O](#), [Loffredo C](#), [Bowman E](#), [Mechanic L](#), [Perlmutter D](#), [Jones R](#), [Shields PG](#), [Harris C](#). **Int J Cancer.** 2009 Jul 22. [Epub ahead of print]
- 4. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers.** [Seike M](#), [Goto A](#), [Okano T](#), [Bowman ED](#), [Schetter AJ](#), [Horikawa I](#), [Mathe EA](#), [Jen J](#), [Yang P](#), [Sugimura H](#), [Gemma A](#), [Kudoh S](#), [Croce CM](#), [Harris CC](#). **Proc Natl Acad Sci U S A.** 2009 Jul 21;106(29):12085-90. Epub 2009 Jul 13.
- 5. Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians.** [Enewold L](#), [Mechanic LE](#), [Bowman ED](#), [Zheng YL](#), [Yu Z](#), [Trivers G](#), [Alberg AJ](#), [Harris CC](#). **Cancer Epidemiol Biomarkers Prev.** 2009 Jan;18(1):215-22.
- 6. International Lung Cancer Consortium: pooled analysis of sequence variants in DNA repair and cell cycle pathways.** [Hung RJ](#), [Christiani DC](#), [Risch A](#), [Popanda O](#), [Haugen A](#), [Zienolddiny S](#), [Benhamou S](#), [Bouchardy C](#), [Lan Q](#), [Spitz MR](#), [Wichmann HE](#), [LeMarchand L](#), [Vineis P](#), [Matullo G](#), [Kiyohara C](#), [Zhang ZF](#), [Pezeshki B](#), [Harris C](#), [Mechanic L](#), [Seow A](#), [Ng DP](#), [Szeszenia-Dabrowska N](#), [Zaridze D](#), [Lissowska J](#), [Rudnai P](#), [Fabianova E](#), [Mates D](#), [Foretova L](#), [Janout V](#), [Bencko V](#), [Caporaso N](#), [Chen C](#), [Duell EJ](#), [Goodman G](#), [Field JK](#), [Houlston RS](#), [Hong YC](#), [Landi MT](#), [Lazarus P](#), [Muscat J](#), [McLaughlin J](#), [Schwartz AG](#), [Shen H](#), [Stucker I](#), [Tajima K](#), [Matsuo K](#), [Thun M](#), [Yang P](#), [Wiencke J](#), [Andrew AS](#), [Monnier S](#), [Boffetta P](#), [Brennan P](#). **Cancer Epidemiol Biomarkers Prev.** 2008 Nov;17(11):3081-9.

7. [Occupation, gender, race, and lung cancer.](#) Amr S, Wolpert B, Loffredo CA, Zheng YL, Shields PG, Jones R, Harris CC. **J Occup Environ Med.** 2008 Oct; 50 (10):1167-75.

- 8. [Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor \(EGFR\) phosphorylation events associated with mutated EGFR compared with wild type.](#)** VanMeter AJ, Rodriguez AS, Bowman ED, Jen J, Harris CC, Deng J, Calvert VS, Silvestri A, Fredolini C, Chandhoke V, Petricoin EF 3rd, Liotta LA, Espina V. **Mol Cell Proteomics.** 2008 Oct; 7 (10):1902-24. Epub 2008 Aug 6.
- 9. [Lung cancer survival and functional polymorphisms in MBL2, an innate-immunity gene.](#)** Pine SR, Mechanic LE, Ambs S, Bowman ED, Chanock SJ, Loffredo C, Shields PG, Harris CC. **J Natl Cancer Inst.** 2007 Sep 19;99(18):1401-9. Epub 2007 Sep 11.
- 10. [Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier.](#)** Seike M, Yanaihara N, Bowman ED, Zanetti KA, Budhu A, Kumamoto K, Mechanic LE, Matsumoto S, Yokota J, Shibata T, Sugimura H, Gemma A, Kudoh S, Wang XW, Harris CC. **J Natl Cancer Inst.** 2007 Aug 15;99(16):1257-69. Epub 2007 Aug 8.
- 11. [Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors.](#)** Mechanic LE, Bowman ED, Welsh JA, Khan MA, Hagiwara N, Enewold L, Shields PG, Burdette L, Chanock S, Harris CC. **Cancer Epidemiol Biomarkers Prev.** 2007 Feb;16(2):214-22.
- 12. [Quantitative detection of p53 mutations in plasma DNA from tobacco smokers.](#)**
Hagiwara N, Mechanic LE, Trivers GE, Cawley HL, Taga M, Bowman ED, Kumamoto K, He P, Bernard M, Doja S, Miyashita M, Tajiri T, Sasajima K, Nomura T, Makino H, Takahashi K, Hussain SP, Harris CC. **Cancer Res.** 2006 Aug 15; 66 (16):8309-17.
- 13. [MDM2 SNP309 and SNP354 are not associated with lung cancer risk.](#)**
Pine SR, Mechanic LE, Bowman ED, Welsh JA, Chanock SC, Shields PG, Harris CC. **Cancer Epidemiol Biomarkers Prev.** 2006 Aug; 15 (8):1559-61.
- 14. [Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.](#)**
Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, Harris CC. **Cancer Cell.** 2006 Mar; 9 (3):189-98.

PROSTATE CANCER:

(Case-Control)

15. [**Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer.**](#) Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, Yfantis HG, Stephens RM, Croce CM. **Cancer Res.** 2008 Aug 1;**68(15):6162-70.**
16. [**Expression of microRNAs and protein-coding genes associated with perineural invasion in prostate cancer.**](#) Prueitt, RL, Yi M, Hudson RS, Wallace TA, Howe TM, Yfantis HG, Lee DH, Stephens RM, Liu CG, Calin GA, Croce CM, Ambs S. **Prostate.** 2008 Aug 1; **68 (11):1152-64.**
17. [**Tumor immunobiological differences in prostate cancer between African-American and European-American men.**](#) Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, Stephens RM, Caporaso NE, Loffredo CA, Ambs S. **Cancer Res.** 2008 Feb 1;**68(3):927-36.**

BREAST CANCER

(Case-Case)

18. [**A stromal gene signature associated with inflammatory breast cancer.**](#) Boersma BJ, Reimers M, Yi M, Ludwig JA, Luke BT, Stephens RM, Yfantis HG, Lee DH, Weinstein JN, Ambs S. **Int. J Cancer.** 2008 Mar 15; **122(6):1324-32.**
19. [**Inflammation and IGF-I activate the Akt pathway in breast cancer.**](#) Prueitt RL, Boersma BJ, Howe TM, Goodman JE, Thomas DD, Ying L, Pfiester CM, Yfantis HG, Cottrell JR, Lee DH, Remaley AT, Hofseth LJ, Wink DA, Ambs S. **Int. J Cancer.** 2007 Feb 15; **120(4):796-805.**
20. [**A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide.**](#) Glynn SA, Boersma BJ, Howe TM, Edvardsen H, Geisler SB, Goodman JE, Ridnour LA, Lønning PE, Børresen-Dale AL, Naume B, Kristensen VN, Chanock SJ, Wink DA, Ambs S. **Clin Cancer Res.** 2009 Jun 15;**15(12):4165-73. Epub 2009 Jun 9.**
21. [**Differences in the tumor microenvironment between African-American and European-American breast cancer patients.**](#) Martin DN, Boersma BJ, Yi M, Reimers M, Howe TM, Yfantis HG, Tsai YC, Williams EH, Lee DH,

Stephens RM, Weissman AM, Ambs S. *PLoS One*. 2009; 4 (2): e4531. Epub 2009 Feb 19.

22. [The mannose-binding lectin \(MBL2\) haplotype and breast cancer: an association study in African-American and Caucasian women.](#) Bernig T, Boersma BJ, Howe TM, Welch R, Yadavalli S, Staats B, Mechanic LE, Chanock SJ, Ambs S. *Carcinogenesis*. 2007 Apr; 28 (4):828-36. Epub 2006 Oct 27.

23. [Association of MTHFR gene polymorphisms with breast cancer survival.](#) Martin DN, Boersma BJ, Howe TM, Goodman JE, Mechanic LE, Chanock SJ, Ambs S. *BMC Cancer*. 2006 Oct 27; 6: 257.

24. [Association of breast cancer outcome with status of p53 and MDM2 SNP309.](#) Boersma BJ, Howe TM, Goodman JE, Yfantis HG, Lee DH, Chanock SJ, Ambs S. *J Natl Cancer Inst*. 2006 Jul 5;98(13):911-9.

COLON CANCER

(Case-Case)

25. [Plasma microRNAs: a potential biomarker for colorectal cancer?](#) Schetter AJ and Harris CC. *Gut*. 2010. 58(10):1318-9.

26. [Association of Inflammation-Related and microRNA Gene Expression with Cancer-Specific Mortality of Colon Adenocarcinoma.](#) Schetter AJ, Nguyen G, Bowman ED, Mathé E, Yuen ST, Hawkes JE, Lueng SY, and Harris CC. *Clinical Cancer Research*. 2009. 15(18): 5878-87.

27. [MiRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus and associations with survival.](#) Mathé EA, Nguyen G, Bowman ED, Budhu A, Schetter AJ, Braun R, Reimers M, Kumamoto K, Hughes D, Altorki NK, Liu CG, Wang XW, Yanaihara N, Hagiwara N, Dannenberg AJ, Miyashita M, Croce CM, Harris CC. *Clinical Cancer Research*. 2009. 15(19):6192-200.

28. [MicroRNA expression is associated with prognosis and therapeutic outcome in colon adenocarcinoma.](#) Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, GK, Liu CG, Calin GA, Croce CM, Harris CC. *Journal of the American Medical Association*. 2008. 299(4):425-436.